Regeneron Pharmaceuticals, Inc.
Close on Nov 20, 2026Market cap $95.24BP/E 20.3Yield –
Regeneron Pharmaceuticals Direct Clinical R&D — Libtayo (cemiplimab) by Quarter
Direct Clinical R&D — Libtayo (cemiplimab) ($M) ($M)
Regeneron Pharmaceuticals Direct Clinical R&D — Libtayo (cemiplimab): $13.4M in Q3 2026, down 25.6% from a year earlier.
Where the Q3 2026 figure comes from
“R&D Expenses Table (FY2026Q3): Libtayo (cemiplimab) | 13.4 | 18.0 | (4.6) | 48.7 | 57.3 | (8.6)”
Source: Form 10-Q (regn-20260930.htm, filed 2026-10-30) ↗
Reported in Form 10-Q / 10-K MD&A — Research and Development Expenses by Clinical Program.
quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
Cite this data
StockData. (2026). Regeneron Pharmaceuticals Direct Clinical R&D — Libtayo (cemiplimab) ($M), quarterly Q3 2017–Q3 2026 [Data set]. Compiled from Regeneron Pharmaceuticals SEC filings and investor materials. https://stockdatahq.com/stocks/regn/kpis/rd-prog-libtayo
See every metric in the Regeneron Pharmaceuticals KPI table. Data updated Nov 4, 2026.
See a number that looks wrong?